Foot and Mouth Disease Vaccine
Foot-and-mouth disease is a viral disease that infects cloven-hoofed animals (pigs, cows, goats, sheep, etc.), causes high fever and blisters, and has a high fatality in young animals, which has a great influence on the livestock economy.
The foot-and-mouth disease vaccine developed by Pharos Vaccine is an efficient and safe vaccine that reveals high positive conversion rate and titer of antibody against foot-and-mouth disease in pigs. In the vaccine, it is used an independently developed chimeric recombinant protein as the immunogen based on protein engineering, and applied a novel adjuvant technology to resolve the safety problems of conventional inactivated virus vaccines.
The foot-and-mouth disease protein vaccine technology of our company has been registered for a patent not only in Korea but also 13 other countries including China, the United States, and Europe, and obtained New Excellent Technology (NET) certificate from the Ministry of Agriculture, Food and Rural Affairs in 2018. Also, we obtained a new biologic approval from the Korean government in 2019 and are proceeding with domestic commercialization, and we are also conducting active discussions for overseas export with foreign countries including China and Vietnam.
Characteristics and Advantages of the Pharos Vaccine Foot-and-Mouth Disease Vaccine
Factor | Pharos Vaccine’s FMD vaccine | FMD inactivated virus vaccine |
---|---|---|
Medicinal agent | Recombinant protein | Foot and Mouth Disease Virus |
Spill accident | Safe No infectivity and pathogenicity |
Risky Can cause infection and disease |
Process safety | Very high No virus in process |
Moderate Live virus in process |
Infection by vaccine | Fundamentally impossible No virus in vaccine |
Rare but possible Can be contaminated by live virus |
NSP Ab | Not detected | Intermittently detected |
Production facility (Cost) |
Normal bio-medicine GMP plant (Relatively Low) |
Bio-safety level 3 GMP plant (Relatively High) |
Modified vaccine against mutant FMD virus |
Can be developed and supplied in 2 ~ 3 months |
Need 6 ~24 months to develop vaccine strain |
Development Stages
Development of immunogen
Development of formulations
Efficacy and safety test
Clinical trial (field)
Approval
Launching